PAHC vs PCRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 09, 2026

PAHC

33.7
AI Score
VS
PCRX Wins

PCRX

44.3
AI Score

Investment Advisor Scores

PAHC

34score
Recommendation
SELL

PCRX

44score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric PAHC PCRX Winner
Forward P/E 13.8313 6.7522 PCRX
PEG Ratio 1.6791 11.2121 PAHC
Revenue Growth 4.8% 6.2% PCRX
Earnings Growth 24.6% -30.0% PAHC
Tradestie Score 33.7/100 44.3/100 PCRX
Profit Margin 6.6% 2.0% PAHC
Beta 1.00 1.00 Tie
AI Recommendation SELL HOLD PCRX

Relative Price Performance (Last 90 Days)

PAHC 1M: +5.4% · 3M: +13.9% PCRX 1M: +7.0% · 3M: +8.6%

Current Technical Phase

PAHC

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 45.7 · Price: $35.62

PCRX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 49

RSI (14): 49.0 · Price: $25.36

Fundamentals Snapshot

Metric PAHC PCRX
Market Cap
Forward P/E 10.7 7.4
Trailing P/E 15.1 74.0
Revenue (TTM)
Revenue Growth 0.0% 0.1%
Gross Margin 0.3% 0.8%
Operating Margin 0.1% 0.1%
EPS 2.42 0.34
Dividend Yield 0.01%

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.